CutisPharma announces FDA approval of FIRVANQ™

CUTISPHARMA ANNOUNCES FDA APPROVAL OF FIRVANQ™ FOR TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED […]